Cerebrolysin General Information

Cerebrolysin is a biotechnologically prepared peptide that stimulates neurotrophic regulation in the central nervous system.

Cerebrolysin is used worldwide for treatment of ischemic and hemorrhagic stroke, traumatic brain injuries, to treat different forms of dementia (vascular dementia, Alzheimer’s disease) and cognitive disorders and to prevent cognitive decline after brain injuries.

Patients with either acute or degenerative neurological diseases benefit from the neuro-protective and neuro-regenerative properties of Cerebrolysin.

Cerebrolysin is injected in doses of up to 5 ml intramuscularly and up to 10 ml intravenously. In the case of higher doses, infusions are recommended (infusion duration 15 – 60 minutes).

Cerebrolysin is a multi-modal neuropeptide drug which improves the brain's ability for self-repair by stimulating neurorecovery.

Cerebrolysin is used for treatment of ischemic and hemorrhagic stroke, traumatic brain injuries (TBI), different forms of dementia (vascular dementia, Alzheimer’s disease) and cognitive disorders and to prevent cognitive decline after brain injuries.

Cerebrolysin is a multi-modal neuropeptide drug with a fast onset of action that helps to regain and maintain the independence of patients suffering from stroke, TBI, dementia and cognitive impairment.

Cerebrolysin improves the brain's ability for self-repair by stimulating neuro-regeneration.

Safety of Cerebrolysin

Cerebrolysin is safe and well tolerated!

The experience with Cerebrolysin during many years of clinical application, the information from post-marketing surveillance studies, and the safety data from double-blind, placebo-controlled clinical trials indicate an extremely high degree of safety (e.g. significat reduction of mortality in CASTA study1)

According to EMA classification, Cerebrolysin is in the “SAFE” category (PSUR reporting required only every 13 years).

In general, reported adverse drug reactions from Cerebrolysin treated patients are transient and mild in intensity.

The most frequently reported adverse reactions with Cerebrolysin are

dizziness

headache

sweating

nausea

Please note that the handling is very important. Please find more information in our dosage recommendation.

Cerebrolysin - Mode of Action

Cerebrolysin is a neurotrophic peptidergic drug with multimodal pharmacological properties indicated for the treatment of acute and chronic CNS disorders. The pathophysiological mechanisms targeted by Cerebrolysin belong to two distinct categories:

Pathological events and cascades caused by an injury or a degenerative disease and

Endogenous repair and recovery processes which constitute defense against an injury or progressing disease.

The natural repair and recovery processes are switched on within the CNS immediately after an injury. These processes also play important role in the continuous defense against progressing neurodegeneration characteristic of chronic CNS disorders (e.g. Alzheimer’s disease). Two major mechanisms regulate recovery from injuries at the molecular level: neurotrophic (NTF) and sonic hedgehog (Shh) signaling pathways. These signaling pathways regulate cellular processes of neurogenesis, angiogenesis, dendrite arborization, axonal sprouting, myelination, and remodeling of the neurovascular unit.

The pathological events and cascades after stroke or trauma lead to secondary injuries (additional loss of neural tissue and its interconnectivity) which further compromise motor and cognitive functions of a patient. Among the most relevant molecular processes targeted by Cerebrolysin in the acute phase of an injury are elements of the ischemic cascade, like excitotoxicity, uncontrolled apoptosis, overactivation of proteolytic enzymes, and overproduction of reactive oxygen species (ROS). In the early post-acute phase, lasting up to several weeks, Cerebrolysin prevents formation of toxic protein aggregates (amyloidosis), and lowers the level of inflammatory processes which further contribute to neurodegeneration.